peptide cost FAQ

Switch to less frequent administration if pharmacokinetics permit. Growth hormone secretagogues like CJC-1295 have half-lives allowing 3–5× weekly dosing instead of daily. This cuts monthly syringe and alcohol prep costs by 50–70% while maintaining therapeutic effect through pulsatile release patterns. For compounds requiring daily administration due to short half-lives, cost reduction requires either lowering dose (if clinically viable) or switching to a more affordable compound with similar mechanism.

Purchase the next-largest vial size and reconstitute with enough bacteriostatic water to create the concentration you need. If you require 3mg per dose but vials come in 5mg or 10mg sizes, buy the 5mg vial and reconstitute with 1.67mL bacteriostatic water. This creates a 3mg/mL concentration, allowing you to draw exactly 1mL per administration. The unused 2mg from the vial can support a second dose at 2mg if protocol flexibility allows, or be discarded at day 28 if not used within the stability window.

Prioritize compounds with longer half-lives and lower required doses. SLU-PP-332 at 10mg weekly costs less monthly than Tesofensine at 500mcg daily despite similar per-mg pricing because weekly administration reduces both peptide consumption and supply costs. Alternatively, implement intermittent dosing schedules where the compound's mechanism allows. Five days on, two days off reduces monthly dose requirements by 28% without fully interrupting receptor engagement in compounds where continuous saturation isn't required for effect.

Use native IGF-1. The 10-minute half-life allows precise temporal control of receptor activation. Administer the peptide, measure the acute response within 15–30 minutes, and observe complete clearance within 60–90 minutes. IGF-1 LR3's extended circulation makes it inappropriate for studies examining transient signaling events or dose-response curves where you need clean washout between experimental conditions. The question of whether IGF-1 LR3 is worth it becomes moot if your endpoint requires signaling that terminates rather than sustains. Select the tool that matches the mechanism being studied.

IGF-1 LR3 demonstrates superior stability post-reconstitution because the structural modifications that confer IGFBP resistance also reduce susceptibility to proteolytic degradation. While both peptides require refrigerated storage at 2–8°C after reconstitution with bacteriostatic water, the lower handling frequency of IGF-1 LR3 (84 vial openings versus 250+) reduces cumulative exposure to temperature fluctuations and contamination risk. Store lyophilized powder at −20°C and reconstitute only the volume needed for 2–4 weeks at a time. Track reconstitution dates and discard vials older than 28 days post-mixing to maintain potency. Small-batch synthesis from suppliers like Real Peptides ensures each lot starts with maximum purity, extending viable storage duration.

Consider MK 677 as an alternative if your research question centers on growth hormone secretagogue receptor activation rather than direct IGF-1R agonism. MK-677 (ibutamoren) stimulates endogenous GH release, which secondarily increases hepatic IGF-1 production. Creating a different signaling cascade than exogenous IGF-1 administration. The oral bioavailability of MK-677 simplifies dosing in long-term studies, but the indirect mechanism introduces GH-mediated effects beyond IGF-1 signaling. Whether IGF-1 LR3 is worth it versus MK-677 depends entirely on whether your model requires isolated IGF-1 receptor activation or can tolerate the broader endocrine effects of GH secretagogue activity.

Choose IGF-1 LR3. Calculate total peptide consumption across the full study period rather than comparing vial prices. A 12-week protocol with daily dosing requires approximately 8.4 mg of IGF-1 LR3 at $1,512–2,016 total cost versus 25–40 mg of native IGF-1 at $2,250–5,600. The crossover point occurs around 4–6 weeks. Any study longer than this becomes more cost-effective with the LR3 variant despite the higher per-milligram price. Budget constraints actually favor IGF-1 LR3 in extended protocols because total expenditure decreases while dosing reliability improves.